002004:SZSEHuapont Life Sciences Co.,Ltd. Analysis

The stock is trading above its 20‑day (5.49) and 50‑day (5.35) SMAs and also above the 200‑day SMA (4.79), indicating a clear bullish trend. MACD has turned bullish with the line crossing above the signal, and the RSI sits at a moderate 58, suggesting room for further upside without being overbought. Volume is increasing, providing solid support at roughly 5.30 and a near‑term resistance around 5.74, while the market sentiment index reads 72.9 (Greed), reinforcing short‑term momentum.
However, fundamentals lag the price action: revenue grew modestly at 5 % YoY but the company posted a negative profit margin and EPS of –0.07, with a ROE near zero. Debt‑to‑equity is high at 53 % and the DCF‑derived fair value (~1.25 CNY) is far below the current price of 5.63 CNY, implying significant overvaluation. The 3.55 % dividend yield appears unsustainable given the zero payout ratio and weak earnings, adding to the downside risk despite the technical strength.